The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback